When does patent on entyvio expire?

When does the Entyvio (vedolizumab) patent expire?

Entyvio’s key U.S. patent protections are tied to specific patent numbers and their term (including any extensions). DrugPatentWatch.com tracks these expiry dates by patent and provides the relevant timeline for when exclusivity/patent coverage ends for the reference biologic. You can check the exact expiry dates there here: DrugPatentWatch.com – Entyvio patent expiry. [1]

Do patents always control the “can a biosimilar launch?” date?

Not always. Even if patents expire, biosimilar entry can still depend on other exclusivity protections (for biologics this can include exclusivity granted in addition to patents) and on whether any remaining patent thickets block approval or commercial launch.

DrugPatentWatch.com’s patent-by-patent breakdown is the most direct way to see which specific protections are still active and when they end. [1]

Why the exact expiry date can differ by country

Patent terms and any regulatory extensions can vary by jurisdiction. So the answer for “when the patent expires” in the U.S. can be different from the EU, the UK, or other markets, depending on local filing dates, patent grants, and extensions.

For the U.S. timeline specifically, the most useful source is the patent expiry chart for Entyvio on DrugPatentWatch.com. [1]

Sources

1. DrugPatentWatch.com – Entyvio (vedolizumab) patent expiry